Ovarian cancer diagnosis and treatment

Conserved cell state dynamics reveal targetable resistance patterns in ovarian high-grade serous carcinoma

The paper identifies conserved cell states in ovarian high-grade serous carcinoma that correlate with poor prognosis and presents actionable targets for improving platinum response.

Organoids serve as viable in vitro model for functional precision medicine for mesonephric-like adenocarcinoma of the ovary

The paper demonstrates that ovarian cancer organoids derived from mesonephric-like adenocarcinoma can be used for functional precision medicine, showing sensitivity to binimetinib and resistance to standard chemotherapeutics.

Reconstruction of epithelial transcriptional trajectories reveals heterogeneous progression and early therapy-resistance programs in high-grade serous carcinomaprecursors

This study reconstructs transcriptional trajectories of Fallopian-tube epithelium to show STICs occupy diverse positions along a progression continuum and exhibit variable PARPi resistance signatures.

Interferon Beta Drives Therapy Resistance in a Patient Derived Model of High Grade Serous Ovarian Cancer

This study shows that IFN-beta drives therapy resistance in HGSOC models through cell-autonomous signaling, independent of DNA damage.

Spatial transcriptomic profiling of ovarian clear cell carcinoma reveals heterogeneity in OXPHOS and EMT gradients

This study uses spatial transcriptomics to reveal OXPHOS and EMT gradients in ovarian clear cell carcinoma, linking metabolic shifts and LCN2 expression to tumor heterogeneity and outcomes.

Cancer-Associated Mesothelial Cells Drive Immune Escape and Therapy Resistance in Ovarian Cancer

This study identifies cancer-associated mesothelial cells (CAMCs) as drivers of immune escape and therapy resistance in ovarian cancer by altering immune cell infiltration and function.

Ascites-Driven Modulation of Cell Phenotypes and Proteomes: Implications for Cancer Progression

This study examines how malignant ascites affects cancer cell proteomes and phenotypes, finding that ascites enhances cell viability and spheroid formation but does not hinder chemotherapy response assessments in ex vivo models.

HOOK2 downregulation compromises the tumorigenic and stemness properties of ovarian cancer cells by increasing endoplasmic reticulum stress

This study shows that reducing HOOK2 levels in ovarian cancer cells decreases tumor growth, migration, and stemness by increasing endoplasmic reticulum stress and cell death.

Integrated single-cell whole genome sequencing and spatial transcriptomics reveal latent intra-tumoral heterogeneity in ovarian cancer

This study uses single-cell whole genome sequencing and spatial transcriptomics to uncover intra-tumoral heterogeneity in ovarian cancer, revealing evolutionary relationships and functionally consequential copy number alterations.

Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer

This study evaluates CHK1i+LDHU therapy in HGSOC, showing it kills cancer cells and reprograms the tumor microenvironment to enhance anti-tumor immune responses.

Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer

The paper shows that modifying the tumor microenvironment's extracellular matrix improves chemotherapy response in ovarian cancer models.

Single-cell spatial atlas of high-grade serous ovarian cancer unveils MHC class II as a key driver of spatial tumor ecosystems and clinical outcomes

Cyclic immunofluorescence of 265 high-grade serous ovarian carcinomas and random-forest feature ranking identify cancer-cell MHC-II as an adjusted predictor of longer survival marking immune-activated tumor-stroma hotspots.

Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

This study develops a humanized xenograft model of high-grade serous ovarian cancer to evaluate immunotherapy, finding no treatment response but identifying immune-excluded tumor phenotypes.

IdentifiHR: predicting homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression

IdentifiHR predicts homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression, achieving 85% accuracy in TCGA and 91% in an independent cohort.

Simpler predictive models provide higher accuracy for ovarian cancer detection

This paper demonstrates that a simpler logistic regression model using protein biomarkers outperforms a more complex method incorporating cfDNA features in ovarian cancer detection.

Comparative proteomic analysis of the ECM composition of the human omentum and mesentery, the main sites of ovarian cancer metastasis

This study compares the extracellular matrix composition of the human omentum and mesentery using proteomics to identify potential factors contributing to ovarian cancer metastasis.

Combined inhibition of NAD synthesis and C-terminal binding protein cooperatively induce cell death and inhibit growth of High Grade Serous Ovarian Carcinoma

The paper shows that combining CtBP inhibitors with NAD synthesis inhibitors enhances cell death and inhibits growth of high-grade serous ovarian carcinoma.

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines

This study shows that combining MEK and PI3K-Akt inhibition enhances anti-tumor effects in LGSOC cells and may overcome resistance to MEK inhibitors.

The prion-like protein Doppel: A soluble biomarker steering ovarian cancers peritoneal to circulatory dissemination

This paper identifies Doppel as a specific biomarker for ovarian cancer, showing its association with tumor subtypes, early detection, and dissemination mechanisms.

Quantitative Proteomics Identifies Conserved Proteins and Altered Regulation of Mucin-16 in Low Grade Serous Ovarian Cancers

The paper identifies conserved protein alterations and elevated MUC16 in low-grade serous ovarian cancers through quantitative proteomics and validation across multiple datasets.

Development and validation of a computational tool to predict treatment outcomes in cells from High-Grade Serous Ovarian Cancer patients

The paper develops and validates a computational tool to predict treatment outcomes in HGSOC cells, showing its potential for preclinical research and personalized medicine.

Organoid Models Derived from Primary Tumors and Patient-Derive Xenograft Tumors Reflect Platinum Sensitivity of Ovarian Cancer Patients

This study shows that organoids derived from patient-derived xenografts (PDXOs) reflect the chemotherapy response of ovarian cancer patients similarly to organoids directly from primary tumors (PDOs).

FSTL3 is a biomarker of poor prognosis and is associated with immunotherapy resistance in ovarian cancer.

This study identifies FSTL3 as a biomarker of poor prognosis and immunotherapy resistance in ovarian cancer, showing its role in promoting a mesenchymal phenotype and immunosuppressive microenvironment.

Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models

The paper uses single cell mass cytometry to identify protein modules associated with carboplatin resistance and sensitivity in ovarian cancer models.

Longitudinal Prediction of Drug Response in High-Grade Serous Ovarian Cancer Organoid Cultures Aligning with Clinical Responses

The paper validates a high-grade serous ovarian cancer organoid platform's ability to predict drug responses over time, showing clinical relevance for targeted therapies.

Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer cell lines and isogenic models

This study profiles 36 ovarian cancer cell lines to identify genetic and gene expression signatures associated with platinum response, revealing cell line sensitivity and resistance to cisplatin and carboplatin.

Loss of the predicted cell adhesion molecule MPZL3 promotes EMT and chemoresistance in ovarian cancer

This study shows that loss of MPZL3 promotes EMT and chemoresistance in ovarian cancer by reducing adhesion and increasing drug resistance.

Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma

This study identifies ARID1A mutation and low CD3+ TIL levels as prognostic markers for relapse in low-stage clear cell ovarian carcinoma.

Suppression of Ovarian Cancer Cell Proliferation is Associated with Upregulation of Cell-Matrix Adhesion Programs and Integrin-β4-Induced Cell Protection from Cisplatin.

This study shows that integrin-β4 upregulation suppresses ovarian cancer cell proliferation and protects cells from cisplatin, suggesting a role in chemoresistance.

Stromal mediated DNA damage promotes high grade serous ovarian cancer initiation

This study identifies high-risk mesenchymal stem cells (hrMSCs) that drive DNA damage and promote high-grade serous ovarian cancer initiation in fallopian tube epithelium.